| Month | Product Name | Regulatory Filing Details | Connect |
|---|---|---|---|
| December | Atorvastatin Calcium Trihydrate [Form-I] | USA | ![Atorvastatin Calcium Trihydrate [Form-I]](/_next/image?url=%2Fimages%2Fhpapi-cont-1.png&w=32&q=75){kind=small} ![Atorvastatin Calcium Trihydrate [Form-I]](/images/hpapi-cont-1.png) |
| Nilotinib Premix (HPMC AS) | USA | | |
| Abemaciclib | Canada DMF | | |
| Sumatriptan Succinate | Japan DMF | | |
| Tafamidis Meglumine | Canada DMF | | |
| Rivaroxaban (Process-II) | USA | | |
| Naratriptan Hydrochloride | Russia DMF | | |
| Lomustine | Russia DMF | | |
| Fondaparinux Sodium | Saudi Arabia | | |
| Fondaparinux Sodium | EU | | |
| November | Dapagliflozin Propanediol | Singapore DMF | |
| Dapagliflozin Amorphous | Indonesia | | |
| Empagliflozin | Singapore DMF | | |
| Empagliflozin | Australia DMF | | |
| Carfilzomib | EU | | |
| Empagliflozin | Saudi Arabia | | |
| Pemetrexed Disodium | Saudi Arabia | | |
| Linagliptin | UK | | |
| October | Lurasidone hydrochloride | Taiwan DMF | |
| Tucatinib Hemiethanolate | India | | |
| Carfilzomib | Japan DMF | | |
| Dasatinib Monohydrate | Saudi Arabia | | |
| Empagliflozin | Malaysia DMF | | |
| Montelukast Sodium | Benin DMF | | |
| Naproxen Sodium | Malaysia DMF | | |
| Tizanidine Hydrochloride | CEP DMF Filed | | |
| September | Dapagliflozin Propanediol | Europe (CEP) | |
| Palonosetron Hydrochloride | Brazil DMF | | |
| Azacitidine | Saudi Arabia | | |
| Erubilin | Saudi Arabia | | |
| Valsartan, Essential Amorphous Form | Europe (CEP) | | |
| Palbociclib | Australia DMF | | |
| Gemcitabine Hydrochloride | Saudi Arabia | | |
| Mirabegron (alpha) | Saudi Arabia | | |
| Deucravacitinib | Brazil DMF | | |
| August | Tucatinib Copovidone ASD | USDMF | |
| Lenalidomide Povidone Premix | Egypt DMF | | |
| Edoxaban Tosylate Monohydrate | Brazil DMF | | |
| Ruxolitinib Hemifumarate | Australia DMF | | |
| Cetirizine Dihydrochloride | Egypt DMF | | |
| Apixaban | Singapore DMF | | |
| Apixaban | Sweden | | |
| July | Edoxaban Tosylate | USDMF | |
| Voriconazole | Russia DMF | | |
| Relugolix | India | | |
| Liraglutide | Saudi Arabia | | |
| Permethrin | Saudi Arabia | | |
| June | Docetaxel Anhydrous | Kenya | |
| Palonosetron Hydrochloride USP | Ethiopia | | |
| Cabazitaxel | Kenya | | |
| Tucatinib Hemiethanolate | Brazil DMF | | |
| Finerenone | Brazil DMF | | |
| May | Dapagliflozin Amorphous | Switzerland | |
| Nilotinib Hydrochloride Monohydrate | Indonesia | | |
| April | Bempedoic acid | Russia DMF | |
| March | Montelukast Sodium | Japan DMF | |
| Apixaban | Taiwan DMF | | |
| Palbociclib | Canada DMF | | |
| Deucravacitinib | USDMF | | |
| Finerenone | USDMF | | |
| Tucatinib | USDMF | | |
| Voclosporin | Brazil DMF | | |
| Lanreotide | Brazil DMF | | |
| Pomalidomide | | ||
| Vonoprazan Fumarate | Korea DMF | | |
| Palbociclib | Korea DMF | | |
| Ezetimibe (Unmicronized) | Korea DMF | | |
| Fexofenadine HCl (Form-1) -FXA4 process | CEP Submitted | | |
| Amlodipine Besylate (TY45) | CEP Submitted | | |
| Tucatinib Hemiethanolate | USDMF | | |
| Tizanidine Hydrochloride USP (TZN-Process) | USDMF | | |
| Enzalutamide Premix (20% w/w) | USDMF | | |
| Pazopanib HCl | EUDMF | | |
| Atorvastatin Calcium Trihydrate form-1 [ATO-3 process] | CEP Submitted | | |
| Ezetimibe (Micronized) | Korea DMF | | |
| February | Montelukast Sodium | Japan DMF | |
| Pioglitazone Hydrochloride | Canada DMF | | |
| Cabozantinib S- Maleate (N2 Form) | Korea DMF | | |
| Palbociclib | Singapore DMF | | |
| Ferric Carboxy Maltose | Saudi Arabia | | |
| January | Fexofenadine Form I | Brazil DMF | |
| Sacubitril/ Valsartan | Canada DMF | | |
| Dasatinib Monohydrate | Taiwan DMF | | |
| Pazopanib | Taiwan DMF | |
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.